


We have presented the Graphical Abstract text and image for your article below. This brief summary of your work will appear in the contents pages of the issue in which your article appears.



### Antiproliferative activity of new 2-glyco-3-nitro-1,2-dihydroquinolines and quinolines synthesized under solventless conditions promoted by neutral alumina

V. Luque-Agudo, José M. Padrón, E. Román, J. A. Serrano and M. V. Gil\*

This paper describes the syntheses of new 2-glyco-3-nitro-1,2-dihydroquinolines and 2-glyco-3-nitroquinolines by one-pot aza-Michael–Henry-dehydration reactions using green procedures, such as a minimal amount of solvent combined with an heterogeneous catalyst (neutral alumina). The reactivity of a nitro group-double bond system has also been investigated; thus, addition of indole or pyrrole to *N*-formylated 1,2-dihydroquinolines has been studied. Finally, the antiproliferative activity of these new compounds has been evaluated against a panel of six human solid tumor cell lines, and compared to pharmacological reference compounds, finding that their activity is in the low micromolar range and that the carbohydrate moiety configuration modulates GI<sub>50</sub> values.

Please check this proof carefully. Our staff will not read it in detail after you have returned it.

Please send your corrections either as a copy of the proof PDF with electronic notes attached or as a list of corrections. **Do not edit the text within the PDF or send a revised manuscript** as we will not be able to apply your corrections. Corrections at this stage should be minor and not involve extensive changes.

**Proof corrections must be returned as a single set of corrections, approved by all co-authors. No further corrections can be made after you have submitted your proof corrections as we will publish your article online as soon as possible after they are received.**

Please ensure that:

- The spelling and format of all author names and affiliations are checked carefully. You can check how we have identified the authors' first and last names in the researcher information table on the next page. **Names will be indexed and cited as shown on the proof, so these must be correct.**
- Any funding bodies have been acknowledged appropriately and included both in the paper and in the funder information table on the next page.
- All of the editor's queries are answered.
- Any necessary attachments, such as updated images or ESI files, are provided.

Translation errors can occur during conversion to typesetting systems so you need to read the whole proof. In particular please check tables, equations, numerical data, figures and graphics, and references carefully.

Please return your **final** corrections, where possible within **48 hours** of receipt, by e-mail to: njc@rsc.org. If you require more time, please notify us by email.

## Funding information

Providing accurate funding information will enable us to help you comply with your funders' reporting mandates. Clear acknowledgement of funder support is an important consideration in funding evaluation and can increase your chances of securing funding in the future.

We work closely with Crossref to make your research discoverable through the Funding Data search tool (<http://search.crossref.org/funding>). Funding Data provides a reliable way to track the impact of the work that funders support. Accurate funder information will also help us (i) identify articles that are mandated to be deposited in **PubMed Central (PMC)** and deposit these on your behalf, and (ii) identify articles funded as part of the **CHORUS** initiative and display the Accepted Manuscript on our web site after an embargo period of 12 months.

Further information can be found on our webpage (<http://rsc.li/funding-info>).

### What we do with funding information

We have combined the information you gave us on submission with the information in your acknowledgements. This will help ensure the funding information is as complete as possible and matches funders listed in the Crossref Funder Registry.

If a funding organisation you included in your acknowledgements or on submission of your article is not currently listed in the registry it will not appear in the table on this page. We can only deposit data if funders are already listed in the Crossref Funder Registry, but we will pass all funding information on to Crossref so that additional funders can be included in future.

### Please check your funding information

The table below contains the information we will share with Crossref so that your article can be found *via* the Funding Data search tool. **Please check that the funder names and grant numbers in the table are correct and indicate if any changes are necessary to the Acknowledgements text.**

Funder name	Funder's main country of origin	Funder ID (for RSC use only)	Award/grant number
European Regional Development Fund	European Union	501100008530	GR15022
Banco Santander	Spain	100010784	Unassigned

Q1

## Researcher information

Please check that the researcher information in the table below is correct, including the spelling and formatting of all author names, and that the authors' first, middle and last names have been correctly identified. **Names will be indexed and cited as shown on the proof, so these must be correct.**

If any authors have ORCID or ResearcherID details that are not listed below, please provide these with your proof corrections. Please ensure that the ORCID and ResearcherID details listed below have been assigned to the correct author. Authors should have their own unique ORCID iD and should not use another researcher's, as errors will delay publication.

Please also update your account on our online [manuscript submission system](#) to add your ORCID details, which will then be automatically included in all future submissions. See [here](#) for step-by-step instructions and more information on author identifiers.

First (given) and middle name(s)	Last (family) name(s)	ResearcherID	ORCID iD
V.	Luque-Agudo		
José M.	Padrón		
E.	Román		
J. A.	Serrano		
M. V.	Gil	I-3146-2015	0000-0002-6236-7241

## Queries for the attention of the authors

Journal: **NJC**

Paper: **c8nj03372b**

Title: **Antiproliferative activity of new 2-glyco-3-nitro-1,2-dihydroquinolines and quinolines synthesized under solventless conditions promoted by neutral alumina**

For your information: You can cite this article before you receive notification of the page numbers by using the following format: (authors), New J. Chem., (year), DOI: 10.1039/c8nj03372b.

Editor's queries are marked on your proof like this **Q1**, **Q2**, etc. and for your convenience line numbers are indicated like this 5, 10, 15, ...

Please ensure that all queries are answered when returning your proof corrections so that publication of your article is not delayed.

Query reference	Query	Remarks
Q1	Funder details have been incorporated in the funder table using information provided in the article text. Please check that the funder information in the table is correct.	
Q2	Please confirm that the spelling and format of all author names is correct. Names will be indexed and cited as shown on the proof, so these must be correct. No late corrections can be made.	
Q3	Please check that the Graphical Abstract text fits within the allocated space indicated on the front page of the proof. If the entry does not fit between the two horizontal lines, then please trim the text and/or the title.	
Q4	A citation to Table 2 has been added here, please check that the placement of this citation is suitable. If the location is not suitable, please indicate where in the text the citation should be inserted.	
Q5	The sentence beginning "However, for those..." has been altered for clarity. Please check that the meaning is correct.	
Q6	The sentence beginning "However, the C-6-bromo-..." has been altered for clarity, please check the meaning has not changed.	

# Antiproliferative activity of new 2-glyco-3-nitro-1,2-dihydroquinolines and quinolines synthesized under solventless conditions promoted by neutral alumina†

V. Luque-Agudo,<sup>a</sup> José M. Padrón,<sup>b</sup> E. Román,<sup>a</sup> J. A. Serrano<sup>a</sup> and M. V. Gil<sup>ib</sup> \*<sup>a</sup>

This paper describes the syntheses of new 2-glyco-3-nitro-1,2-dihydroquinolines and 2-glyco-3-nitroquinolines by one-pot aza-Michael–Henry–dehydration reactions using a minimal amount of solvent and neutral alumina as the heterogeneous catalyst. The reactivity of the nitro group–double bond system has also been investigated; thus, the addition of indole or pyrrole to *N*-formylated 1,2-dihydroquinolines has been studied. Finally, the cytotoxicity and antiproliferative activity of these new compounds have been evaluated against a panel of six human solid tumor cell lines and compared to pharmacological reference compounds, finding that their activity is in the low micromolar range and that the carbohydrate moiety configuration modulates the GI<sub>50</sub> values.

Received 6th July 2018,  
Accepted 2nd October 2018

DOI: 10.1039/c8nj03372b

rsc.li/njc

## Introduction

Quinoline **1** was first isolated from coal tar in 1834 by F. F. Runge, and it is still the main source of commercial quinoline.<sup>1</sup> Cinchona bark extract (genus *Rubiaceae*) has been extensively used to combat malaria. Detailed analysis allowed the identification of more than 20 alkaloids, where quinine **2**, cinchonidine **3**, quinidine **4** and cinchonine **5** (Fig. 1) were those with the highest biological activity. In general terms, quinoline **1** derivatives exhibit different biological activities,<sup>2–5</sup> and their syntheses have been reviewed.<sup>6</sup>

In spite of their numerous applications, there are only a few reported examples of quinoline **1** derivatives containing acyclic or cyclic carbohydrate moieties, and none at C-2.<sup>7–11</sup>

Regarding the synthesis of nitroquinolines, three general methods have usually been used for their preparation, such as nitration of quinolines,<sup>12</sup> reaction of 3-nitroquinolines *N*-oxides with a limited number of reagents,<sup>13</sup> and a modified Friedländer synthesis.<sup>14,15</sup>

Dihydroquinolines also present a broad spectrum of biological activities and are very important in medicinal and pharmaceutical chemistry.<sup>16</sup> Synthetic methods of chiral 1,2-




Fig. 1 Structures of compounds **1–5**.

dihydroquinolines are very limited,<sup>17,18</sup> thus, due to the potential application of these substances, the synthetic challenge of preparing them using carbohydrates, which are considered as attractive products for drug design, as chiral auxiliaries has been considered.

Alternative reaction media are being considered in order to comply with the current legislation on environmental, safety and health policies, such as performing the reactions in the absence of solvent,<sup>19</sup> and the combination of this technique with the use of heterogeneous catalysts, which constitutes one of the most powerful green synthetic tools.

In this work, the synthesis of 3-nitro-1,2-dihydroquinolines and 3-nitroquinolines bearing carbohydrate moieties at C-2 has been carried out under solventless conditions promoted by neutral alumina, considering, additionally, their possible antiproliferative activity. To the best of our knowledge, there are no reported examples of this type of compound. Due to this lack of available literature, we have based our synthesis on that reported by Yao *et al.*<sup>15</sup> and adapted it to the asymmetric version using nitroolefins derived from carbohydrates as chiral

<sup>a</sup> IACYS-Unidad de Química Verde y Desarrollo Sostenible, Departamento de Química Orgánica e Inorgánica, Facultad de Ciencias, Universidad de Extremadura, 06006 Badajoz, Spain. E-mail: vgil@unex.es

<sup>b</sup> BioLab Instituto Universitario de Bio-Orgánica Antonio González (IUBO-AG), Centro de Investigaciones Biomédicas de Canarias (CIBICAN), Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8nj03372b


inducers. Ballini *et al.*<sup>20</sup> improved the reaction conditions by avoiding the use of DABCO and benzene. Moreover, since the influence of the structure of the carbohydrate moiety on the cytotoxic and antiviral activity of certain 3-nitrochromenes has been described,<sup>21</sup> the influence of the stereochemistry of the carbohydrate moiety inserted at C-2 of the novel synthesized quinoline-derivatives on their antiproliferative activity has been studied.

## Results and discussion

2-Glyco-3-nitro-1,2-dihydroquinolines **9a–11c** were prepared by one-pot aza-Michael–Henry-dehydration reactions between carbohydrate derived nitroalkenes **6** and **7** and 2-aminobenzaldehydes **8a–c**, using neutral alumina as the catalyst,<sup>20</sup> heating at 60 °C and adding dichloromethane (3.12 mol%) to homogenize the mixture (Scheme 1). The results are summarized in Table 1. Both nitroalkenes were used to compare the asymmetry induced by the chiral center at C-3 of compounds **6** and **7** and to study whether that skeleton affects the potential antiproliferative activity of the new compounds (Table 2).

The assignment of C-2 configuration for **9a–c** and **10a–c** + **11a–c** was tentatively made, considering that nitroalkenes **6** and **7** adopt a preferred conformation<sup>22</sup> in which their C-2 *Si* and *Re* faces, respectively, are less hindered for the nucleophilic attack of the amine group present in **8a–c**, and, therefore, more favourable (Fig. 2). Processes involving nitroalkene **6** were completely diastereoselective, since only one of the two possible diastereoisomers was detected. The observed diastereoselectivity could be explained taking into account the steric hindrance caused by the acetate group at C-3 of compound **6**, not found in **7**.

Our group proposes a correlation between the value of  $J_{1',2}$  and the absolute configuration assigned to C-2 in 3-nitro-1,2-dihydroquinolines with peracetylated carbohydrate moieties:



Scheme 1 Reaction between nitroalkenes **6** and **7** and aminobenzaldehydes **8a–c**.

Table 1 Reaction times, yields and product ratios for **9a** and **10a–c** + **11c** products

	<b>6</b>			<b>7</b>			
	R <sup>2</sup>	<i>t</i> (days)	Yield (%)	Product	<i>t</i> (days)	Yield (%)	Product (ratio)
H	1	89		<b>9a</b>	1.5	88	<b>10a</b> + <b>11a</b> (1 : 1.6)
Cl	2	63		<b>9b</b>	1.5	92	<b>10b</b> + <b>11b</b> (1 : 1.6)
Br	3	59		<b>9c</b>	2	87	<b>10c</b> + <b>11c</b> (1 : 1.1)

Table 2 Correlation between C-2 configuration and value of  $J_{1',2}$

Compound	$J_{1',2}$ (Hz)	C-2 configuration
<b>9a</b>	9.5	<i>S</i>
<b>9b</b>	9.5	<i>S</i>
<b>9c</b>	9.5	<i>S</i>
<b>10a</b>	0	<i>S</i>
<b>11a</b>	6.0	<i>R</i>
<b>10b</b>	1.0	<i>S</i>
<b>11b</b>	5.5	<i>R</i>
<b>10c</b>	1.0	<i>S</i>
<b>11c</b>	5.0	<i>R</i>





Fig. 2 Preferential attack of **8a–c** on nitroalkene **6**.

thus, if C-1' presents the *S* configuration (*D-galacto*), for compounds with C-2(*S*) configuration, the coupling constants  $J_{1',2}$  will be large (5–10 Hz), whereas for compounds having the C-2(*R*) configuration, these same constants will have a small value (0–2 Hz). When C-1' presents the *R* configuration (*D-manno*), the values of the coupling constants are opposite with respect to those of the previous case. This correlation has also been observed, and in some cases confirmed by X-ray diffraction, in other 3-nitro-2*H*-thiochromenes and in 3-nitro-2*H*-chromenes synthesized in our lab.<sup>23</sup>

3-Nitroquinolines **12a–c** and **13a–c** were obtained by treatment of 1,2-DHQs **9a–c** or **10a–c** + **11a–c** with a mixture of sodium dichromate, wet silica gel (50% w/w) and sodium bisulfate<sup>24</sup> at room temperature (Scheme 2), with short reaction times and in good yields (Table 3).

Deacetylated quinolines **14a–15c** were synthesized (Scheme 3) to improve the solubility of the new compounds in aqueous medium, which is the closest medium to cellular tissue. The results are summarized in Table 4.


The *trans*-nitro group–double bond system is preserved in the skeleton of the 1,2-DHQs; for this reason, we studied their reactivity as acceptors in Michael additions. Thus, reactions between 1,2-DHQs, which were firstly *N*-formylated<sup>25</sup> to avoid oxidation to the corresponding quinolines, and indole **17** or pyrrole **18** were carried out using basic alumina as the catalyst,<sup>26</sup> heating at 70 °C and adding dichloromethane (3.12 mol%) (Schemes 4 and 5).



Scheme 2 Oxidation of **9a–c** and **10a–c** + **11a–c** to quinolines **12a–c** and **13a–c**.

1 **Table 3** Reaction times and yields for the oxidation of 1,2-DHQs **9a–c** and **10a–c** + **11a–c** to quinolines **12a–13c**

Compound	R <sup>2</sup>	Time (h)	Yield (%)
<b>12a</b>	H	1.5	83
<b>12b</b>	Cl	3.25	87
<b>12c</b>	Br	2.25	71
<b>13a</b>	H	0.5	47
<b>13b</b>	Cl	1.75	76
<b>13c</b>	Br	3	85




**12a–c**, R<sup>1</sup> = *D-galacto*-(CHOAc)<sub>4</sub>-CH<sub>2</sub>OAc  
**13a–c**, R<sup>1</sup> = *D-manno*-(CHOAc)<sub>4</sub>-CH<sub>2</sub>OAc  
**14a–c**, R<sup>3</sup> = *D-galacto*-(CHOH)<sub>4</sub>-CH<sub>2</sub>OH  
**15a–c**, R<sup>3</sup> = *D-manno*-(CHOH)<sub>4</sub>-CH<sub>2</sub>OH

a, R<sup>2</sup> = H  
 b, R<sup>2</sup> = Cl  
 c, R<sup>2</sup> = Br

**Scheme 3** Deacetylation of carbohydrate moieties.

10 **Table 4** Reaction times and yields for deacetylated compounds **14a–c** and **15a–c**

Compound	R <sup>2</sup>	Time (h)	Yield (%)
<b>14a</b>	H	1	93
<b>14b</b>	Cl	1	95
<b>14c</b>	Br	1	66
<b>15a</b>	H	1.5	42
<b>15b</b>	Cl	1	53
<b>15c</b>	Br	1	67




R<sup>1</sup> = *D-galacto*-(CHOAc)<sub>4</sub>-CH<sub>2</sub>OAc  
**16a**, R<sup>2</sup> = H  
**16b**, R<sup>2</sup> = Cl  
**16c**, R<sup>2</sup> = Br

**Scheme 4** Addition of indole **17** to compounds **16a–c**.

For processes involving indole **17**, the two *Z/E* rotamers of the same diastereoisomer were isolated, except in the case of **16c**, in which only **20c** was isolated. However, for those involving pyrrole **18**, only *E* rotamers were isolated in pure form, although *Z* ones were also detected by <sup>1</sup>H-NMR analysis of the crude reaction. As the NOE experiments were inconclusive, the assignment of *Z/E* isomerism was performed by taking into account previous studies. Nagarajan *et al.*<sup>27</sup> concluded that in the case of *N*-formyltetrahydroquinolines, the major isomer is *E*, according to the comparison of chemical shifts of their NMR spectra signals and those of lilolidone, an analogue product.

### Antiproliferative activity

Previous theoretical quantitative structure–activity relationship studies applied to *trans*-2-(2-nitrovinyl)-furan predicted that



R<sup>1</sup> = *D-galacto*-(CHOAc)<sub>4</sub>-CH<sub>2</sub>OAc

**16a**, R<sup>2</sup> = H

**16b**, R<sup>2</sup> = Cl

**16c**, R<sup>2</sup> = Br

**Scheme 5** Addition of pyrrole **18** to compounds **16a–c**.

more than 50% of the biological activity lies in the *trans*-nitro group–double bond system.<sup>28</sup> Antiproliferative activity results of structurally-related compounds synthesized by our group<sup>23,29</sup> support this hypothesis. For that reason, the previously mentioned activity of compounds **9a–16c**, including the starting nitroolefins **6** and **7**, was evaluated against a panel of six human solid tumor cell lines: A-549 (non-small cell lung), SW1573 (non-small cell lung), HBL-100 (breast), T-47D (breast), HeLa (cervix) and WiDr (colon). The GI<sub>50</sub> values (concentration of compound required to inhibit 50% of tumor cell growth) are depicted in Table 5. Evaluation was accomplished by using a slightly modified version of the protocol of the National Cancer Institute (NCI) of the United States.<sup>30,31</sup> The standard anticancer drugs etoposide, cisplatin and 5-fluorouracil were used as references for comparative purposes.

As can be observed in Table 5, the GI<sub>50</sub> values of the selected compounds are, in general, worse than those of the reference patterns. Antiproliferative activity oscillates between moderate and low, but, despite that, some conclusions can be inferred:

Among the acetylated 3-nitro-1,2-dihydroquinolines with the *D-galacto*-configuration moiety, **9a–c**, the activity decreases in the order R<sup>2</sup> = H > Cl > Br, for all tumor cell lines. For this set of compounds, **9b** was found to be more effective than 5-fluorouracil against T-47D and WiDr cell lines, and is also slightly less active than the pharmacological patterns etoposide and cisplatin.

The activity of the acetylated 3-nitroquinolines with the *D-galacto*-configuration moiety, **12a–c**, is lower than that of their precursors, the 1,2-dihydroquinolines. However, the C-6-bromo-substituted compound **12c** has moderate activity, exhibiting values comparable to those of **9a** for the HeLa cell line. Even so, compound **12b** remains the most active in the series against T-47D and WiDr over 5-fluorouracil.

It is noteworthy that upon deacetylating the carbohydrate moiety of the 3-nitroquinolines, all compounds turn out to be inactive against all cell lines, except **14c**, which exhibits moderate activity, with values very similar to those of 5-fluorouracil against T-47D and WiDr.

Pure compound **10a**, bearing a *D-manno*-configuration moiety, has relatively high GI<sub>50</sub> values, being inactive against T-47D and WiDr cell lines. However, it is interesting that the activity of the **10c** + **11c** mixture, which shows a markedly good activity profile, is more effective than 5-fluorouracil and similar to the activity exhibited by cisplatin.

1 Table 5 Antiproliferative activity (GI<sub>50</sub>) against human solid tumor cell lines and human fibroblasts<sup>a</sup>

Compound	A549 (lung)	HBL-100 (breast)	HeLa (cervix)	SW1573 (lung)	T-47D (breast)	WiDr (colon)	BJ-hTert (fibroblast)
GI <sub>50</sub> ± s <sub>D</sub> (μM)							
6	17 ± 4	14 ± 2	16 ± 2	1.7 ± 0.7	19 ± 2	18 ± 3	42 ± 11
7	20 ± 2	10 ± 3	18 ± 1	2.1 ± 0.4	22 ± 4	24 ± 5	11 ± 3
9a	29 ± 4	73 ± 29	33 ± 8	67 ± 26	71 ± 25	53 ± 16	>100
12a	70 ± 28	72 ± 26	38 ± 7	72 ± 39	>100	90 ± 18	n.t.
14a	>100	>100	>100	>100	>100	>100	n.t.
10a	57 ± 4	34 ± 8	30 ± 1	26 ± 8	>100	>100	n.t.
15a	>100	>100	>100	>100	>100	>100	n.t.
16a	56 ± 17	83 ± 23	43 ± 4	63 ± 10	54 ± 15	56 ± 16	>100
9b	25 ± 9	26 ± 6	24 ± 9	40 ± 9	23 ± 6	30 ± 3	>100
12b	37 ± 5	>100	26 ± 6	90 ± 1	32 ± 1	47 ± 13	n.t.
14b	>100	>100	>100	>100	>100	>100	n.t.
15b	>100	>100	>100	>100	>100	>100	n.t.
16b	15 ± 2	17 ± 1	16 ± 3	12 ± 3	18 ± 4	19 ± 4	>100
9c	88 ± 17	97 ± 5	52 ± 3	91 ± 12	93 ± 12	82 ± 24	>100
12c	53 ± 16	89 ± 2	44 ± 9	41 ± 13	82 ± 17	59 ± 9	>100
14c	29 ± 5	32 ± 3	32 ± 7	54 ± 1	50 ± 10	49 ± 1	>100
10c + 11c	3.3 ± 0.4	8.2 ± 2.6	3.4 ± 0.6	2.6 ± 0.6	2.6 ± 0.2	4.3 ± 0.4	>100
15c	>100	>100	>100	>100	>100	>100	n.t.
16c	19 ± 4	31 ± 8	18 ± 4	15 ± 3	28 ± 7	26 ± 4	>100
Etoposide	0.7 ± 0.2	2.3 ± 0.9	3.0 ± 0.9	15 ± 2	22 ± 6	23 ± 3	1.3 ± 0.6
5-Fluorouracil	2.2 ± 0.3	5.5 ± 2.3	1.5 ± 5	4.3 ± 1.6	47 ± 18	49 ± 7	5.5 ± 0.5
Cisplatin	2.1 ± 0.6	1.9 ± 0.2	2.0 ± 0.3	3.0 ± 0.4	15 ± 3	26 ± 6	14 ± 3

<sup>a</sup> Values are mean of two to four experiments. n.t. = not tested.

A significant change of activity was observed upon the *N*-formylation of the 1,2-dihydroquinolines; thus, all of them present between moderate and good GI<sub>50</sub> values, being of the same order or even lower in the cases of **16b** and **16c** for tumor cell lines HeLa, T-47D and WiDr, with respect to 5-fluorouracil.

For the 3-nitro-1,2-dihydroquinolines and their derivatives, **19a-b**, **20a-c** and **21b-c**, it can be concluded that the C-6 substituent of the ring influences the antiproliferative activity of these compounds, but it is not possible to infer a clear trend in this regard.

## Experimental

### Materials and methods

All chemicals were purchased from commercial sources and used directly, without further purification. Preparative TLC was performed using silica gel (Merck 60 GF<sub>254</sub>). TLC was performed on precoated Merck Kieselgel 60 GF<sub>254</sub> aluminum backed plates; TLC spots were visualized by UV light. NMR spectra were recorded on a Bruker AC/PC instrument (500 MHz for <sup>1</sup>H and 125 MHz for <sup>13</sup>C) with tetramethylsilane as the internal reference and deuterated chloroform or dimethyl sulfide as the solvent. Coupling constants were recorded in Hz. The characterization of NMR signals was based on homonuclear double-resonance and DEPT experiments. High resolution mass spectra were recorded on an Autospec (Micromass) spectrometer, at the Centro de Investigación Tecnológica e Innovación (CITIUS) from the Universidad de Sevilla. Infrared spectra were recorded on an IR3000 Thermo Electron Corporation spectrophotometer in the range between 4000 and 600 cm<sup>-1</sup>.

The evaluation of the antiproliferative activity was accomplished following the protocol of the NCI of the United States.<sup>30,31</sup> For each compound, the cells were exposed to serial

decimal dilutions in the range of 0.001–100 μM for a period of 48 h. After exposure, the SRB method was applied to determine the optical density of each cell at 530 nm (main) and 620 nm (secondary). For each product concentration, the percentage of growth (PG) according to the NCI formulae was calculated.

### Synthetic procedures

**General procedure for 2-glyco-3-nitro-1,2-dihydroquinolines 9a–11c.** To a heterogeneous mixture of nitroalkenes **6** and **7** (32 (1 g, 2.31 mmol) and the appropriate aminobenzaldehyde **8a-c** (2.31 mmol), neutral alumina (2.31 g) and four drops of dichloromethane (to initially homogenize the mixture) were added. The mixture was stirred at 60 °C until reaction completion (monitored by TLC, 1 : 5 hexane–diethyl ether). The crude product was extracted with methanol, filtered and washed with the same solvent until the alumina became white. If necessary, diastereoisomers were purified by PTLC (1 : 5 hexane–diethyl ether).

**General procedure for 2-glyco-3-nitroquinolines 12a–13c.** Quinolines were synthesized using a protocol reported in the literature.<sup>24</sup>

**General procedure for the deacetylated products 14a–15c.** To a solution of **12a–13c** (1 mmol) in 90% methanol (15 mL), potassium carbonate (0.57 g) was added. The suspension was stirred at room temperature for 1 hour (TLC, 3 : 1, benzene–methanol). The crude reaction was acidified to pH ~ 6 with diluted HCl (if a solid appears) or Amberlite IR-120 (H<sup>+</sup>), which was then filtered. Pure products were crystallized from methanol.

**General procedure for *N*-formyl-1,2-dihydroquinolines 16a–c.** A mixture of **9a–c** (1 mmol), formic acid (4.7 mmol) and acetic anhydride (4.8 mmol) was stirred at room temperature for 1–2 hours (TLC, 1 : 5 hexane–diethyl ether). After evaporation, the

1 residue was dissolved in dichloromethane (10 mL), washed  
with 5% sodium bicarbonate solution and dried with magne-  
sium sulfate. The extract was evaporated to yield pure com-  
pounds **16a–c**.

5 **General procedure for the addition of indole or pyrrole to N-**  
**formyl-1,2-dihydroquinolines.** To a mixture of *N*-formyl-1,2-  
dihydroquinolines **16a–c** (1 mmol) and indole or pyrrole  
(1 mmol), activated basic alumina (1 g) and four drops of  
10 dichloromethane (to initially homogenize the mixture) were  
added and stirred at 60–70 °C for two days. The crude reaction  
was extracted with methanol and filtered. Compounds were  
purified by PTLC (1 : 1 hexane–ethyl acetate, 2 elutions).

## 15 Conclusions

In this paper, we report on the synthesis of new 3-nitro-1,2-  
dihydroquinolines and derivatives bearing a carbohydrate  
moiety at C-2 using green procedures, since these processes  
have been carried out in the absence of solvent and with a  
20 heterogeneous catalyst. Moreover, the antiproliferative activity  
of some of the products described herein has been studied,  
finding that their GI<sub>50</sub> values are of the same order as those of  
pharmacological reference compounds in some of the cases.

## 25 Conflicts of interest

There are no conflicts to declare.

## 30 Acknowledgements

This work was supported by the Gobierno de Gobierno de  
Extremadura-Ayuda a Grupos de Investigación Catalogados  
and Fondo Europeo de Desarrollo Regional (Grant GR15022).  
35 We also thank the Universidad de Extremadura, Plan de  
Iniciación a la Investigación, Desarrollo Tecnológico e Innova-  
ción 2016 and Grupo Banco Santander for providing a fellow-  
ship to Verónica Luque-Agudo.

## 40 Notes and references

1 R. Heusch and B. Laverkusen, *Ullmann's Encyclopedia of*  
*Industrial Chemistry*, 2000, , DOI: 10.14356007: a09\_297.  
2 (a) O. Bilker, V. Lindo, M. Panico, A. E. Etienne, T. Paxton,  
45 A. Dell, M. Rogers, R. E. Sinden and H. R. Morris, *Nature*,  
1998, **392**, 289; (b) G. Roma, M. D. Braccio, G. Grossi,  
F. Mattioli and H. Ghia, *Eur. J. Med. Chem.*, 2000,  
**35**, 1021; (c) Y.-L. Chen, K.-C. Fang, J.-Y. Sheu, S.-L. Hsu  
and C.-C. Tzeng, *J. Med. Chem.*, 2000, **44**, 2374;  
50 (d) P. A. Winstanley, *Parasitol. Today*, 2000, **16**, 146.  
3 (a) K.-C. Fang, Y.-L. Chen, J.-Y. Sheu, T.-C. Wang and C.-  
C. Tzeng, *J. Med. Chem.*, 2000, **43**, 3809; (b) J. Chevalier,  
S. Atifi, A. Eyraud, A. Mahamoud, J. Barbe and J.-M. Pages,  
*J. Med. Chem.*, 2001, **44**, 4023; (c) L. T. Phan, T. Jian, Z. Chen,  
55 Y.-L. Qiu, Z. Wang, T. Beach, A. Polemeropoulos and  
Y. S. Or, *J. Med. Chem.*, 2004, **47**, 2965; (d) S. J. Benkovic,

S. J. Baker, M. R. K. Alley, Y.-H. Woo, Y.-K. Zhang, T. Akama,  
W. Mao, J. Baboval, P. T. R. Rajagopalan, M. Wall,  
L. S. Kahng, A. Tavassoli and L. Shapiro, *J. Med. Chem.*,  
2005, **48**, 7468.  
4 (a) K. Majerz-Maniecka, B. Oleksyn, R. Musiol, B. Podeszwa  
5 and J. Polanski, Abstracts of Papers, Joint Meeting on  
Medicinal Chemistry, Vienna, Austria, June 20–23, 2005;  
In *Sci. Pharm.*, 2005, **73** (Suppl. 1), 194; (b) L. Y. Vargas,  
M. V. Castelli, V. V. Kouznetsov, J. M. Urbina, S. N. Lopez,  
M. Sortino, R. D. Enriz, J. C. Ribas and S. Zacchino, *Bioorg.*  
10 *Med. Chem.*, 2003, **11**, 1531; (c) M. Shingh, M. P. Shingh and  
S. Y. Ablordeppey, *Drug Dev. Ind. Pharm.*, 1996, **22**, 377.  
5 (a) L. Dassonneville, A. Lansiaux, A. Wattelet, N. Wattez,  
C. Mahieu, S. V. Miert, L. Pieters and C. Bailly, *Eur.*  
*J. Pharmacol.*, 2000, **409**, 9; (b) L. Dassonneville,  
K. Bonjean, M.-C. De Pauw-Gillet, P. Colson, C. Houssier,  
J. Quentin-Leclerq, L. Angenot and S. Y. Ablordeppey,  
*Bioorg. Med. Chem.*, 2002, **10**, 1337; (c) C. Bailly, *Biochem-*  
15 *istry*, 1999, **38**, 7719; (d) C. Bailly, W. Laine, B. Baldeyrou, M.-  
C. De Pauw-Gillet, P. Colson, C. Houssier, K. Cimanga,  
S. V. Miert, A. J. Vlietinck and L. Pieters, *Anti-Cancer Drug*  
*Des.*, 2000, **15**, 191; (e) M. Chauhan, A. Rana, J. M. Alex,  
A. Negi, S. Singh and R. Kumar, *Bioorg. Chem.*, 2015, **58**, 1.  
6 S. M. Prajapati, K. D. Patel, R. H. Vekariya, S. N. Panchal and  
H. D. Patel, *RSC Adv.*, 2014, **4**, 24463, and references therein.  
7 P. H. Dobbelaar and C. H. Marzabadi, *Tetrahedron Lett.*,  
2010, **51**, 201.  
8 (a) J. S. Yadav, B. V. S. Reddy and B. Padmavani, *Synthesis*, 2004,  
405; (b) J. S. Yadav, B. V. S. Reddy, S. Meraj, P. Vishnumurthy,  
K. Narsimulu and A. C. Kunwar, *Synthesis*, 2006, 2923. 30  
9 (a) C. T. Bahner, N. Hunt and L. M. Rives, *J. Org. Chem.*,  
1960, **25**, 2062; (b) S. Ou, Z. Lin, C. Duan, H. Zhang and  
Z. Bai, *Chem. Commun.*, 2006, 4392.  
10 J. Godlewska, K. Badowska-Roslonek, J. Ramza,  
L. Kaczmarek, W. Peczyńska-Czoch and A. Opolski, *Radiol.*  
35 *Oncol.*, 2004, **38**, 137.  
11 S. Nagarajan and T. M. Das, *Carbohydr. Res.*, 2009, **344**, 1028.  
12 (a) G. Bacharach, A. H. Haut and L. Caroline, *Recl. Trav.*  
*Chim. Pays-Bas*, 1933, 413; (b) B. Arnestad, J. M. Bakke,  
I. Hegbom and E. Ranes, *Acta Chem. Scand.*, 1996, **50**, 556;  
40 (c) J. M. Bakke and E. Ranes, *Synthesis*, 1997, 281;  
(d) M. Bakke, E. Ranes, J. Riha and H. Svensen, *Acta Chem.*  
*Scand.*, 1999, **53**, 141.  
13 (a) H. Nakagawa, T. Higuchi, K. K. Kikuchi, Y. Urano and  
T. Nagano, *Chem. Pharm. Bull.*, 1998, **46**, 1656; 45  
(b) K. S. Sharma, S. Kumari and R. P. Singh, *Synthesis*,  
1981, 316.  
14 (a) K. Schofield and R. S. Theobald, *J. Chem. Soc.*, 1950, 395;  
(b) K. Schofield and R. S. Theobald, *J. Chem. Soc.*, 1951,  
2992; (c) D. W. Ockenden and K. Schofield, *J. Chem. Soc.*, 50  
1953, 3914; (d) H. E. Baumgarten and J. L. Taylor, *J. Am.*  
*Chem. Soc.*, 1957, **79**, 1502.  
15 M. C. Yan, Z. Tu, C. Lin, S. Ko, J. Hsu and C.-F. Yao, *J. Org.*  
*Chem.*, 2004, **69**, 1565.  
16 (a) A. R. Katritzky, S. Rachwal and B. Rachwal, *Tetrahedron*, 55  
1996, **52**, 15031; (b) K. M. Witherup, R. W. Ransom,



- 1 A. C. Graham, A. M. Pitzemberger and S. L. Varg, *J. Am. Chem. Soc.*, 1995, **117**, 6682; (c) R. M. Kariba, P. J. Houghton and A. J. Yenesew, *J. Nat. Prod.*, 2002, **65**, 566; (d) S. W. Elmore, M. J. Coghlan, D. D. Anderson, J. K. Pratt, B. E. Green, A. X. Wang, M. A. Stashko, C. W. Lin, C. M. Tyree, J. N. Miner, P. B. Jacobson, D. M. Wilcox and B. C. Line, *J. Med. Chem.*, 2001, **44**, 4481; (e) P. D. Leeson, R. W. Carling, K. W. Moore, A. M. Moseley, J. D. Smith, G. Stevenson, T. Chan, R. Baker and A. C. Foster, *J. Med. Chem.*, 1992, **35**, 1954.
- 5 17 (a) M. Takamura, K. Funabashi, M. Kanai and M. Shibasaki, *J. Am. Chem. Soc.*, 2000, **122**, 6327; (b) H. Li, J. Wang, H. Xie, L. Zu, W. Jiang, E. N. Duesler and W. Wang, *Org. Lett.*, 2007, **9**, 965; (c) H. Sunden, R. Rios, I. Ibrahim, G.-L. Zhao, L. Eriksson and A. Córdova, *Adv. Synth. Catal.*, 2007, **349**, 827; (d) X. Liu and Y. Lu, *Org. Biomol. Chem.*, 2010, **8**, 4063.
- 10 18 Y.-F. Wang, W. Wang, W. Zhang, S.-P. Luo, B.-L. Li, A.-B. Xia, A.-G. Zhong and D.-Q. Xu, *Chem. – Asian J.*, 2009, **4**, 1834.
- 15 19 *Chemistry in Alternative Reaction Media*, ed. D. J. Adams, P. J. Dyson and S. J. Tavener, Wiley, 2004.
- 20 20 R. Ballini, G. Bosica, D. Fiorini and A. Palmieri, *Green Chem.*, 2005, **7**, 825.
- 25 21 J. M. J. Tronchet, S. Zerelli, N. Dolatshahi and H. Türler, *Chem. Pharm. Bull.*, 1988, **36**, 3725.
- 30 22 (a) J. C. Sowden and M. L. Oftedahl, *J. Org. Chem.*, 1961, **26**, 2153; (b) J. C. Sowden and M. L. Oftedahl, *J. Am. Chem. Soc.*, 1960, **82**, 2303; (c) J. C. Sowden, A. Kirkland and K. O. Lloyd, *J. Org. Chem.*, 1963, **28**, 3516; (d) J. A. Galbis and J. A. Serrano, *An. Quim.*, 1983, **79**, 33.
- 35 23 V. Luque-Agudo, J. Albarrán-Velo, J. G. Fernández-Bolaños, O. López, M. E. Light, J. M. Padrón, I. Lagunes, E. Román, J. A. Serrano and M. V. Gil, *New J. Chem.*, 2017, **41**, 3154.
- 40 24 J. A. Damavandi, M. A. Zolfigol and B. Karami, *Synth. Commun.*, 2001, **31**(20), 3183.
- 45 25 M. L. Hill and R. A. Raphael, *Tetrahedron*, 1990, **46**, 4587.
- 50 26 R. Ballini, R. R. Clemente, A. Palmieri and M. Petrini, *Adv. Synth. Catal.*, 2006, **348**, 191.
- 55 27 K. Nagarajan, M. D. Nair and P. M. Pillai, *Tetrahedron*, 1967, **23**, 1683.
- 28 H. González-Díaz, E. Olazábal, L. Santana, E. Uriarte, Y. González-Díaz and N. Castañedo, *Bioorg. Med. Chem.*, 2007, **15**, 962.
- 29 V. Luque-Agudo, A. M. González-Gutiérrez, I. Lagunes, F. López-Galindo, J. M. Padrón, E. Román, J. A. Serrano and M. V. Gil, *Bioorg. Chem.*, 2016, **69**, 71.
- 30 P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney and M. R. Boyd, *J. Natl. Cancer Inst.*, 1990, **82**, 1107.
- 31 P. Miranda, J. M. Padrón, J. I. Padrón, J. Villar and V. S. Martin, *ChemMedChem*, 2006, **1**, 323.
- 32 (a) J. C. Sowden and D. R. Strobach, *J. Am. Chem. Soc.*, 1960, **82**, 954; (b) J. C. Sowden and R. Schaffer, *J. Am. Chem. Soc.*, 1950, **73**, 4662.